MX2012001420A - Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus. - Google Patents

Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.

Info

Publication number
MX2012001420A
MX2012001420A MX2012001420A MX2012001420A MX2012001420A MX 2012001420 A MX2012001420 A MX 2012001420A MX 2012001420 A MX2012001420 A MX 2012001420A MX 2012001420 A MX2012001420 A MX 2012001420A MX 2012001420 A MX2012001420 A MX 2012001420A
Authority
MX
Mexico
Prior art keywords
formula
pyrrolo
kinase inhibitors
janus kinase
pyridazine derivatives
Prior art date
Application number
MX2012001420A
Other languages
English (en)
Inventor
V Satish Kumar
Pravin L Kotian
Minwan Wu
Yarlagadda S Babu
Tsu-Hsing Lin
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of MX2012001420A publication Critical patent/MX2012001420A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La invención proporciona compuestos de la fórmula I (ver fórmula (I)) o una sal de los mismos como se describe en la presente. La invención también proporciona composiciones farmacéuticas que comprenden el compuesto de la fórmula I, procedimientos para preparar los compuestos de la fórmula I, intermediarios útiles para preparar compuestos de la fórmula I y métodos terapéuticos para suprimir una respuesta inmune o tratar cáncer o una malignidad hematológica usando los compuestos de la fórmula I.
MX2012001420A 2009-07-31 2010-07-30 Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus. MX2012001420A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23049009P 2009-07-31 2009-07-31
PCT/US2010/043987 WO2011014817A1 (en) 2009-07-31 2010-07-30 Pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2012001420A true MX2012001420A (es) 2012-03-26

Family

ID=42670611

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001420A MX2012001420A (es) 2009-07-31 2010-07-30 Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.

Country Status (14)

Country Link
US (1) US20120149691A1 (es)
EP (1) EP2459562A1 (es)
JP (1) JP2013501003A (es)
KR (1) KR20120085738A (es)
CN (1) CN102596959A (es)
AR (1) AR077346A1 (es)
AU (1) AU2010278730A1 (es)
BR (1) BR112012002110A2 (es)
CA (1) CA2769209A1 (es)
IL (1) IL217798A0 (es)
MX (1) MX2012001420A (es)
RU (1) RU2012107101A (es)
TW (1) TW201107330A (es)
WO (1) WO2011014817A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CN106074548A (zh) 2010-09-23 2016-11-09 艾伯维巴哈马有限公司 氮杂金刚烷衍生物的一水合物
WO2012125886A1 (en) * 2011-03-17 2012-09-20 Bristol-Myers Squibb Company Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
AR085436A1 (es) 2011-03-17 2013-10-02 Bristol Myers Squibb Co Derivados de pirrolopiridazina inhibidores de jak3, composiciones farmaceuticas que los contienen y su uso para tratar enfermedades inflamatorias y autoinmunes
US8987268B2 (en) 2011-03-17 2015-03-24 Bristol-Myers Squibb Company Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2012172043A1 (en) 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
US9428511B2 (en) * 2012-09-06 2016-08-30 Bristol-Myers Squibb Company Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
JP6223452B2 (ja) 2012-09-07 2017-11-01 ノバルティス アーゲー インドールカルボキサミド誘導体およびその使用
EP2924026A1 (en) * 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
PL233595B1 (pl) 2017-05-12 2019-11-29 Celon Pharma Spolka Akcyjna Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK
CN109232575B (zh) * 2017-07-10 2022-01-25 中国科学院上海药物研究所 吡咯[1,2-b]哒嗪类化合物或其可药用盐及它们的用途
TWI721483B (zh) * 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US10851102B2 (en) 2019-01-23 2020-12-01 Theravance Biopharma R&D Ip, Llc Imidazole and triazole containing bicyclic compounds as JAK inhibitors
JP2022545364A (ja) * 2019-08-13 2022-10-27 ブリストル－マイヤーズ スクイブ カンパニー Ｉｒａｋ４阻害剤として有用な二環ヘテロアリール化合物
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2022109492A1 (en) * 2020-11-23 2022-05-27 Gossamer Bioservices, Inc. Pyrrolopyridazine compounds as kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US6900208B2 (en) * 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CN101312977B (zh) * 2005-09-22 2012-06-13 布里斯托尔-迈尔斯.斯奎布公司 用作激酶调节剂的稠合杂环化合物
US7531539B2 (en) * 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP2010508315A (ja) * 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
JP5394404B2 (ja) * 2008-02-06 2014-01-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用な置換イミダゾピリダジン類
KR20110050654A (ko) 2008-08-01 2011-05-16 바이오크리스트 파마수티컬즈, 인코퍼레이티드 Ｊａｋ3 억제제로서의 피페리딘 유도체

Also Published As

Publication number Publication date
CA2769209A1 (en) 2011-02-03
IL217798A0 (en) 2012-03-29
BR112012002110A2 (pt) 2018-04-10
US20120149691A1 (en) 2012-06-14
EP2459562A1 (en) 2012-06-06
WO2011014817A1 (en) 2011-02-03
RU2012107101A (ru) 2013-09-10
AR077346A1 (es) 2011-08-17
TW201107330A (en) 2011-03-01
KR20120085738A (ko) 2012-08-01
CN102596959A (zh) 2012-07-18
JP2013501003A (ja) 2013-01-10
AU2010278730A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
MX2012001420A (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.
WO2011031554A3 (en) Heterocyclic compounds as janus kinase inhibitors
WO2011079230A3 (en) Heterocyclic compounds as janus kinase inhibitors
MX2020003458A (es) Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[ 5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3- carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
MY150059A (en) Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
MX2016007371A (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
TW200800990A (en) Azaindole inhibitors of aurora kinases
HK1131608A1 (en) Pyridinone compounds
UA99597C2 (ru) Пиримидилциклопентаны как ингибиторы акт протеинкиназ
SI2054418T1 (sl) Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
WO2009155121A3 (en) Inhibitors of pi3 kinase
UA95641C2 (en) Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
MX2013005445A (es) Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
PE20090506A1 (es) DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
BR112012029994A2 (pt) composto heterocíclicos como inibidores de janus quinase
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
UA100545C2 (ru) Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт
TNSN07440A1 (en) Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same
MX2010007546A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa.
MX336332B (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal